Mind Medicine (MindMed) Inc N.MMED.WR

Primary Symbol: MNMD Alternate Symbol(s): N.MMED.WS | N.MMED.WA | N.MMED

Healthcare

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).

NDAQ:MNMD - Post by User

Mind Medicine (MindMed) Inc > Increase

<< Previous

Bullboard Posts

Next >>

Post by dbottomson Nov 30, 2021 5:19pm

522 Views

Post# 34182415

Increase

either a trading error. Or another announcement coming tonight. 600000 shares popped up 45 percent at end of day.. So assume something is coming. Their research report shows safety of mixing their therapy with ssri.. Which is clearing a big barrier to entry

<< Previous

Bullboard Posts

Next >>

Gold vs. bitcoin, where should you invest?